Advertisement
Advertisement
Mezacar

Mezacar Dosage/Direction for Use

carbamazepine

Manufacturer:

Kusum Healthcare

Distributor:

Kusum Healthcare
Full Prescribing Info
Dosage/Direction for Use
Before deciding to initiate treatment, patients of Han Chinese and Thai origin should whenever possible be screened for HLA-B*1502 as this allele strongly predicts the risk of severe carbamazepine-associated Stevens-Johnson syndrome.
Epilepsy: The dose of carbamazepine should be adjusted to the needs of the individual patient to achieve adequate control of seizures. Determination of plasma levels may help in establishing the optimum dosage. In the treatment of epilepsy, the dose of carbamazepine usually requires total plasma-carbamazepine concentrations of about 4 to 12 micrograms/mL (17 to 50 micromoles/litre) (see Precautions).
Adults: It is advised that with all formulations of Mezacar, a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.
Mezacar should be taken in a number of divided doses although initially 100-200 mg once or twice daily is recommended. This may be followed by a slow increase until the best response is obtained, often 800-1200 mg daily. In some instances, 1600 mg or even 2000 mg daily may be necessary.
Elderly: Due to the potential for drug interactions, the dosage of Mezacar should be selected with caution in elderly patients.
Children and adolescents: It is advised that with all formulations of Mezacar, a gradually increasing dosage scheme is used and this should be adjusted to suit the needs of the individual patient.
Usual dosage 10-20 mg/kg bodyweight daily taken in several divided doses.
Mezacar tablets are not recommended for very young children.
5-10 years: 400 to 600 mg daily (2-3 x 200 mg tablets per day, to be taken in divided doses).
10-15 years: 600 to 1000 mg daily (3-5 x 200 mg tablets per day, to be taken in several divided doses).
>15 years of age: 800 to 1200 mg daily (same as adult dose).
Maximum recommended dose: Up to 6 years of age: 35 mg/kg/day; 6-15 years of age: 1000 mg/day; >15 years of age: 1200 mg/day.
Wherever possible, anti-epileptic agents should be prescribed as the sole antiepileptic agent but if used in polytherapy the same incremental dosage pattern is advised.
When Mezacar is added to existing antiepileptic therapy, this should be done gradually while maintaining or, if necessary, adapting the dosage of the other antiepileptic(s) (see Interactions).
Trigeminal neuralgia: Slowly raise the initial dosage of 200-400 mg daily until freedom from pain is achieved (normally at 200 mg 3-4 times daily). In the majority of patients a dosage of 200 mg 3 or 4 times a day is sufficient to maintain a pain free state. In some instances, doses of 1600 mg Mezacar daily may be needed. However, once the pain is in remission, the dosage should be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.
Elderly: Dosage in Trigeminal neuralgia: Due to drug interactions and different antiepileptic drug pharmacokinetics, the dosage of Mezacar should be selected with caution in elderly patients.
In elderly patients, an initial dose of 100 mg twice daily is recommended. The initial dosage of 100 mg twice daily should be slowly raised daily until freedom from pain is achieved (normally at 200 mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.
For the prophylaxis of manic depressive psychosis in patients unresponsive to lithium therapy: Initial starting dose of 400 mg daily, in divided doses, increasing gradually until symptoms are controlled or a total of 1600 mg given in divided doses is reached. The usual dosage range is 400-600 mg daily, given in divided doses.
Special populations: Renal impairment/Hepatic impairment: No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.
Method of administration: Mezacar is given orally, usually in two or three divided doses. Mezacar may be taken during, after or between meals, with a little liquid e.g. a glass of water.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement